

BELOW IS INFORMATION ON **2 CLINICAL TRIALS ACTIVELY RECRUITING**: If you would like more information in participating in a clinical trial, **Contact Bharti at 404-351-0205 ext 111 or email [blegros@mscalt.org](mailto:blegros@mscalt.org)**


## CHIMES



Chimes is a Phase IV FDA approved Ocrevus (ocrelizumab) study for 2 years with labs, MRIs and doctor visits. You may qualify to participate if you are:

- African American or Hispanic American
- Age 18-65
- Newly diagnosed with Multiple Sclerosis and never had treatment before, or you are transitioning from one of these drug therapies:
  - Interferon      - Gylenya
  - Mayzent        - Tecfidera
  - Copaxone

## ARTIOS



Artios is a Phase 3 FDA approved study with the injectable drug, Kesimpta (ofatumumab), in patients with Relapsing Remitting MS or Secondary Progressive MS. This is a 2 year study with labs, MRIs and doctor visits. You may qualify to participate if you:

- Are age 18 – 60
- Had an MS diagnosis of 10 years or less
- Have had no more than 3 drug therapies and are currently transitioning from Tecfidera or Gilenya as your last drug therapy